[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2020006013A - Variantes con fragmento de fc que tienen una mayor afinidad por el receptor de fc neonatal (fcrn) y una mayor afinidad por al menos un receptor del fragmento de fc. - Google Patents

Variantes con fragmento de fc que tienen una mayor afinidad por el receptor de fc neonatal (fcrn) y una mayor afinidad por al menos un receptor del fragmento de fc.

Info

Publication number
MX2020006013A
MX2020006013A MX2020006013A MX2020006013A MX2020006013A MX 2020006013 A MX2020006013 A MX 2020006013A MX 2020006013 A MX2020006013 A MX 2020006013A MX 2020006013 A MX2020006013 A MX 2020006013A MX 2020006013 A MX2020006013 A MX 2020006013A
Authority
MX
Mexico
Prior art keywords
fragment
increased affinity
receptor
fcrn
variants
Prior art date
Application number
MX2020006013A
Other languages
English (en)
Inventor
Céline Monnet
Philippe Mondon
Harry Meade
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of MX2020006013A publication Critical patent/MX2020006013A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una variante de un polipéptido original que comprende un fragmento de Fc, la variante que tiene una afinidad incrementada por el receptor de FcRn, y una afinidad incrementada por al menos un receptor del fragmento de Fc (FcR) elegido de los receptores de Fc?RI (CD64), Fc?RIIIa (CD16a) y Fc?RIIa (CD32a), en relación con aquella del polipéptido original, caracterizada porque comprende: (i) las cuatro mutaciones 334N, 352S, 378V y 397M; y (ii) al menos una mutación elegida entre 434Y, 434S, 226G, P228L, P228R, 230S, 230T, 230L, 241L, 264E, 307P, 315D, 330V, 362R, 389T y 389K; la numeración es aquella del índice de UE o el equivalente en Kabat.
MX2020006013A 2017-12-15 2018-12-14 Variantes con fragmento de fc que tienen una mayor afinidad por el receptor de fc neonatal (fcrn) y una mayor afinidad por al menos un receptor del fragmento de fc. MX2020006013A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1762217A FR3075200B1 (fr) 2017-12-15 2017-12-15 Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc
PCT/EP2018/084970 WO2019115773A1 (fr) 2017-12-15 2018-12-14 Variants avec fragment fc ayant une affinité augmentée pour fcrn et une affinité augmentée pour au moins un récepteur du fragment fc

Publications (1)

Publication Number Publication Date
MX2020006013A true MX2020006013A (es) 2020-08-17

Family

ID=62816603

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006013A MX2020006013A (es) 2017-12-15 2018-12-14 Variantes con fragmento de fc que tienen una mayor afinidad por el receptor de fc neonatal (fcrn) y una mayor afinidad por al menos un receptor del fragmento de fc.

Country Status (11)

Country Link
US (1) US20210214434A1 (es)
EP (1) EP3724221A1 (es)
JP (2) JP2021508444A (es)
KR (1) KR20200098512A (es)
CN (2) CN118812703A (es)
AU (1) AU2018382593A1 (es)
BR (1) BR112020012016A2 (es)
CA (1) CA3084602A1 (es)
FR (1) FR3075200B1 (es)
MX (1) MX2020006013A (es)
WO (1) WO2019115773A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3101640B1 (fr) 2019-10-07 2024-04-12 Lab Francais Du Fractionnement Lignée cellulaire de monocytes humains et son utilisation en tant que modèle cellulaire de la phagocytose.
CN115515975A (zh) * 2020-05-21 2022-12-23 兹杜斯生命科学有限公司 Fc变体及其制备
KR102341138B1 (ko) 2020-05-31 2021-12-21 주식회사 엑소코바이오 엑소좀의 막단백질 변이체를 포함하는 엑소좀 및 이의 제조방법
KR20220101559A (ko) 2021-01-11 2022-07-19 주식회사 엑소코바이오 과발현된 Fc 수용체 또는 이의 일부를 포함하는 엑소좀 및 이의 제조방법
KR20220106696A (ko) 2021-01-21 2022-07-29 주식회사 엑소코바이오 목적 단백질 또는 펩타이드가 융합가능한 Fc 수용체 또는 이의 일부를 포함하는 재조합 엑소좀 및 이의 용도
WO2023191766A1 (en) * 2022-03-28 2023-10-05 Intervexion Therapeutics, Llc ANTIBODIES WITH ALTERED FcRn AFFINITY

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE141646T1 (de) 1986-04-09 1996-09-15 Genzyme Corp Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
EP2385069A3 (en) * 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
FR2957598B1 (fr) * 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
US20170129966A1 (en) * 2014-06-02 2017-05-11 Laboratoire Français Du Fractionnement Et Des Biotechnologies Production of fc fragments
FR3024453B1 (fr) * 2014-08-01 2018-06-29 Lab Francais Du Fractionnement Procede de production de variants ayant un fc presentant une sialylation amelioree
FR3035879A1 (fr) * 2015-05-07 2016-11-11 Lab Francais Du Fractionnement Mutants fc a activite fonctionnelle modifiee
FR3038517B1 (fr) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
FR3051794A1 (fr) * 2016-05-31 2017-12-01 Lab Francais Du Fractionnement Anticorps pour le traitement de cancers
FR3053688A1 (fr) * 2016-07-06 2018-01-12 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Mutants fc a activite fonctionnelle amelioree

Also Published As

Publication number Publication date
EP3724221A1 (fr) 2020-10-21
US20210214434A1 (en) 2021-07-15
FR3075200B1 (fr) 2022-12-23
BR112020012016A2 (pt) 2020-11-24
JP2021508444A (ja) 2021-03-11
CA3084602A1 (fr) 2019-06-20
FR3075200A1 (fr) 2019-06-21
WO2019115773A1 (fr) 2019-06-20
JP2023134604A (ja) 2023-09-27
CN111601821B (zh) 2024-06-14
KR20200098512A (ko) 2020-08-20
CN118812703A (zh) 2024-10-22
CN111601821A (zh) 2020-08-28
AU2018382593A1 (en) 2020-06-25
RU2020119543A (ru) 2021-12-13

Similar Documents

Publication Publication Date Title
MX2020006013A (es) Variantes con fragmento de fc que tienen una mayor afinidad por el receptor de fc neonatal (fcrn) y una mayor afinidad por al menos un receptor del fragmento de fc.
WO2017006052A3 (fr) UTILISATION DE FRAGMENTS Fc MODIFIÉS EN IMMUNOTHÉRAPIE
MX2020004129A (es) Anticuerpos anti-cd38 y metodos de uso.
MX2016008782A (es) Variantes de region fc con union mejorada de la proteina a.
EA201891495A1 (ru) Биспецифические анти-cd20/анти-cd3 антитела для лечения острого лимфобластного лейкоза
BR112017028550A2 (pt) proteínas de fusão de fragmentos de proteína humana para criar composições de inmunoglobulina fc multimerizadas ordinárias com relação de complemento melhorado
EA201792184A1 (ru) Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
TW201613970A (en) Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
PE20180330A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y metodos para su uso
BR112016022841A8 (pt) Anticorpo igm, iga, igg / igm ou igg / iga, ou um fragmento de ligação ao antígeno do mesmo, composição que o compreende e uso do mesmo
ZA202101358B (en) Chimeric antigen receptors against multiple hla-g isoforms
MX2018014456A (es) Anticuerpos contra alfa-sinucleina y sus usos.
MX2017005150A (es) Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a.
UA116479C2 (uk) БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
PE20190261A1 (es) Anticuerpos que reconocen tau
MX2017011534A (es) Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
PE20150002A1 (es) Anticuerpos anti-fcrn
PE20230381A1 (es) Proteina de union a rgma
EA202191231A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ЭНДОКРИННОЙ ОФТАЛЬМОПАТИИ С ПРИМЕНЕНИЕМ АНТИ-FcRn АНТИТЕЛ
EA201890340A1 (ru) Моноклональное антитело-ингибитор фактора xiia
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MX2015013232A (es) Anticuerpos neutralizadores de flavivirus y metodos de uso de los mismos.
MX2020007555A (es) Anticuerpos potenciadores del factor h y usos de los mismos.
BR112019001156A2 (pt) proteínas de fusão de fragmentos de proteína humana para criar composições de fc de imunoglobulina multimerizadas ordenadas com ligação de receptor fc reforçada